National Health Act 1953 - Amendment determination under subsections 85A(1) and (2) and 88(1C) - Prescription of pharmaceutical benefits by authorised optometrists (No. PB 100 of 2008)

Overview

The National Health Act 1953, as amended by the instrument F2008L03759, addresses the need to provide Australians with reliable, timely, and affordable access to a wide range of medicines through the Pharmaceutical Benefits Scheme (PBS). Enacted by the Commonwealth Government, the Act ensures that benefits are provided by the Commonwealth in accordance with the provisions outlined in Part VII, which is the legislative foundation of the PBS. This legislative instrument, made on 2 October 2008 and commencing on 1 November 2008, amends earlier determinations to align with recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC, an independent expert body, plays a crucial role in advising the Minister on which drugs and medicinal preparations should be available as pharmaceutical benefits, taking into account various factors such as clinical effectiveness, safety, and cost-effectiveness. This amendment aims to enhance the efficiency and accessibility of the PBS by adjusting the forms of certain drugs and the quantities that can be prescribed, ultimately ensuring that the scheme meets the evolving healthcare needs of Australians.

Scope and Application

The National Health Act 1953 Amendment Determination under subsections 85A(1) and (2) and 88(1C), instrumental in the administration of the Pharmaceutical Benefits Scheme (PBS), applies to drugs and medicinal preparations that are declared by the Minister to constitute pharmaceutical benefits. These listed drugs are outlined in subsection 84(1) and include specific forms and quantities that can be prescribed by specified classes of persons, as determined by the Minister. This determination ensures that the PBS provides reliable, timely, and affordable access to a wide range of medicines for all Australians. The Act operates on a national level, extending its reach across the Commonwealth, and applies to the entities and individuals involved in the prescription, supply, and administration of these pharmaceutical benefits. This includes doctors, pharmacists, and patients who are part of the PBS. The Act does not specify exclusions but operates through subordinate instruments to define the scope of the pharmaceutical benefits available under the PBS. The amendments made by this instrument are based on recommendations from the Pharmaceutical Benefits Advisory Committee, which consults with various stakeholders, including healthcare professionals and consumer representatives, to ensure the PBS meets the health needs of Australians.

Key Provisions

The National Health Act 1953 (the Act), as amended by the instrument (F2008L03759), modifies the Pharmaceutical Benefits Scheme (PBS) to ensure the Commonwealth can provide reliable, timely, and affordable access to a wide range of medicines for Australians. The Act, particularly under Part VII, governs the provision of pharmaceutical benefits, with the Minister declaring listed drugs by legislative instrument (sections 85(1) and 85(2)). These declarations determine the specific forms, strengths, and units of the drugs that constitute a pharmaceutical benefit (section 85(3)). Furthermore, the Minister can determine the manner of administration and the brand of the pharmaceutical item (sections 85(5) and 85(6)). The Act also authorises the Minister to make various determinations concerning the prescription of pharmaceutical benefits (sections 85A(1) and 85A(2)). For example, the Minister can determine the maximum quantity or number of units that may be supplied in one prescription, the maximum number of occasions for the supply, and the manner of administration (subsections 85A(2)(a), (b), and (c)). Additionally, section 88(1C) of the Act allows the Minister to determine the pharmaceutical benefits for which an optometrist is authorised to write prescriptions. Under this instrument, the Minister amends the determinations made under subsections 85A(1) and (2), and 88(1C) by legislative instrument number PB 78 of 2008, which came into effect on 1 August 2008. The changes are detailed in Schedule 1 of the instrument and include the addition of a new form of Flurometholone eye drops and alterations to the form and maximum quantity of Polyethylene Glycol 400 with Propylene Glycol. These amendments are set to commence on 1 November 2008. The Act imposes various obligations on the parties it governs. The Minister must consult with the Pharmaceutical Benefits Advisory Committee (PBAC) when making recommendations relevant to medicines on the PBS. The PBAC, an independent expert body, consists of members with diverse qualifications and experience, including representatives from consumer groups, health economists, pharmacists, general practitioners, and specialists. The Minister is required to consider the recommendations of the PBAC when making determinations under the Act. Furthermore, the Act mandates that any amendments to the PBS must be made by legislative instrument and must be in line with the recommendations of the PBAC and the outcome of the consultation process. Failure to comply with the provisions of the Act can result in civil or criminal consequences. However, the instrument does not explicitly state any specific offences, penalties, or civil/criminal consequences for breach. The determinations and amendments under the Act are designed to ensure that the PBS continues to provide affordable and effective access to medicines for all Australians.